Aclidinium bromide + Placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Trial Timeline
Jul 1, 2006 → May 1, 2008
NCT ID
NCT00363896About Aclidinium bromide + Placebo
Aclidinium bromide + Placebo is a phase 3 stage product being developed by AstraZeneca for Chronic Obstructive Pulmonary Disease (COPD). The current trial status is completed. This product is registered under clinical trial identifier NCT00363896. Target conditions include Chronic Obstructive Pulmonary Disease (COPD).
What happened to similar drugs?
20 of 20 similar drugs in Chronic Obstructive Pulmonary Disease (COPD) were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02375724 | Approved | Completed |
| NCT02153489 | Approved | Completed |
| NCT01966107 | Approved | Completed |
| NCT01471171 | Phase 3 | Completed |
| NCT01045161 | Phase 3 | Completed |
| NCT00500318 | Phase 3 | Completed |
| NCT00358436 | Phase 3 | Completed |
| NCT00363896 | Phase 3 | Completed |
Competing Products
20 competing products in Chronic Obstructive Pulmonary Disease (COPD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Levofloxacin 500 | Dr. Reddy's Laboratories | Pre-clinical | 23 |
| mRNA-0184 | Moderna | Phase 1 | 0 |
| Lubiprostone + Lubiprostone + Placebo | Dr. Reddy's Laboratories | Phase 3 | 37 |
| macitentan 10 mg | BML, Inc. | Phase 3 | 32 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 29 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 36 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 23 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 35 |
| THB001 | Third Harmonic Bio | Phase 1 | 11 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 26 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 14 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 29 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 40 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 29 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 44 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 35 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 42 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 21 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 27 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 25 |